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1. Introduction 
The role of T cells as pathogenic effector cells in type 1 diabetes (T1D) is well established. Both 
CD4+ and CD8+ cells can play distinct and highly pathogenic roles mediating diabetogenesis. 
Other cell types including NK, B cells, macrophages and dendritic cells also play coordinate 
roles. Ultimately auto-aggressive T cells invade pancreatic islets focusing destructive force on 
the beta cells that produce insulin. The initial insult may be solely inflammation but 
nonetheless results in loss of insulin production. This chapter will focus on the different T cell 
subtypes including a newly described helper T cell subtype, Th40, which is highly pathogenic 
in T1D.  Discussion will include how auto-aggressive T cells can arise and suggest alternative 
means to control auto-aggressive T cells. The ultimate goal for a successful treatment is to 
control pathogenic effector cells without causing immune suppression, a feat that has yet to be 
achieved. Considering new paradigms about diabetogenesis may provide substantive clues 
towards effectively curing this ravaging disease. 
2. CD4
+
 T cells and inflammation 
CD4+ T cells differentiate and based on immunologic functions and cytokine production are 
grouped into different sub types of T “helper” (Th) cells. Help is provided to CD8 cells in 
the form of IL-2 to drive viral protection or to B cells in the form of IL-4/IL-5 to promote the 
humoral immune arm. Other forms of help include IFN (1, 2) to create activated 
macrophages that aid innate immunity. Naive T cells are polarized by IL-12 to a Th1 
phenotype producing IFN, TNF, IL-2, IL-1 etc., (Fig. 1) leading to localized inflammation 
(3, 4). IL-4 polarizes Th2 cells to produce IL-4, IL-5, IL-10, IL-13 etc., and is associated with 
an anti-inflammatory response. Of further interest is IL-6, which is categorized as a Th2 
cytokine, but atypical of that family IL-6 is pro-inflammatory; suggesting that IL-6 would 
have better fit with Th1 cytokines. 
T cell subsets impact each other’s functional capabilities; IFNinhibits Th2 cells while 
promoting Th1 cells and IL-4 inhibits the Th1 response (5). These T helper subtypes provide 
an interesting back drop for T1D. Th1 cytokines like IFN and TNF have been shown to be 
prominent in driving disease (6). However, IFN-/- mice still develop T1D and when IFN is 
blocked with a neutralizing antibody early in diabetogenesis, disease is exacerbated (7). An 
additional complication is that T cells isolated from IFN-/- mice transfer disease very 
effectively, suggesting that IFN is important for trafficking rather than islet destruction (8). 
When IFN is not available Th17 cells drastically increase in number (7), suggesting a role 
for Th17 cells in T1D development.  
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Fig. 1. Stages of helper T cells 
Th17 cells have been postulated as a distinct T helper subtype that produces IL-17 and IL-22  
(9). Th17 cells are linked to microbial immunity (10, 11) and to autoimmune diseases 
including multiple sclerosis and the experimental autoimmune encephalitis (EAE) mouse 
model of that disease. Studies further link Th17 cells to experimental autoimmune uveitis 
(EAU) (12-14), rheumatoid arthritis (15), systemic lupus erythematosus (16) and to delayed 
airway hypersensitivity (17). Th1 or Th17 cells are capable of becoming pathogenic effector 
cells, however distinguishing surface biomarkers that identify predominantly auto-
aggressive T cells rarely have been forthcoming. The role of Th17 cells as pathogenic effector 
cells in T1D is still debated.  Th17 and diabetes was further explored using a T cell receptor 
(TCR) transgenic model. Cells were isolated from BDC2.5.TCR transgenic mice and 
polarized to a Th1 or Th17 phenotype (18), then transferred to NOD.scid recipients. Th1 
recipients became diabetic more quickly than Th17 recipients (18). When Th17 cells were 
removed and analyzed it was determined that a majority of those cells produced IFN. The 
interpretation was that Th17 cells could convert to Th1 phenotype and the Th1 phenotype 
alone was responsible for disease. However, given that the BDC2.5 TCR recognizes an islet 
antigen, recently determined to be Chromogranin-A and that antigen is always present, the 
T cells from BDC2.5.TCR.Tg mice could never be considered truly naïve. This therefore 
could impact the polarization process.  
Another T helper produced cytokine with high potential in diabetogenesis is IL-6. IL-6 levels 
were reported generally increased in T1D subjects, including long – term diabetics (19) . 
However it also was reported that IL-6 levels are not predictive of outcome or disease 
progression (20). In another demonstration of discordance between human and mouse 
transitional studies, it was shown that blocking IL-6 in young NOD mice prevents disease 
onset (6, 21). While not examined in that study, the inhibition of IL-6 may have impeded the 
generation of Th17 cells. Administration of IL-12 to young NOD mice induces increases in 
IFN producing cells, but interestingly also induces diabetes in IFN receptor knockout mice 
(21). This suggests that control of IFN producing cells alone is inadequate for controlling 
diabetogenesis. These studies indicate a complicated picture with no tightly characterized 
cell type dominating the disease process.  
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3. Tregs and T1D 
A critical player in the T cell dyad of the inflammatory/anti-inflammatory milieu is the 
regulatory T cell subset (Tregs). Tregs function to control effector cells and to diminish the 
inflammatory response. Tregs are generally classified by expression of CD4, CD25hi (the 
alpha chain of the IL-2 receptor) and the transcription factor FoxP3 (22). Other molecules are 
associated with Tregs including GITR, CTLA-4, CD103, CD127lo, and CD62L. Tregs can arise 
naturally or be induced in the periphery.  Naturally arising Tregs develop in the thymus 
and require self-antigen recognition for development. This was demonstrated using 
recombination activating gene, (RAG1 and RAG2) knockout mice that do not develop Tregs 
(23, 24).  In a TCR transgenic mouse model it was shown that Tregs develop in the thymus 
as long as RAG1 and RAG2 are available (24). In the TCR transgenic mice that are RAG-/- 
and therefore do not express endogenous TCR molecules, Tregs do not develop (25, 26). This 
poses an interesting scenario that a set of self – antigen reactive T cells are able to 
preferentially escape negative selection. That possibility poses the central question of 
whether those cells ultimately become pathogenic.  
The other type of Treg is induced in the periphery requiring interactions with antigen and 
polarizing exposure to TGF (Fig. 1). An interesting aspect is that Th17 effector cells can 
arise directly from Tregs (Fig. 1). Polarization studies show that treating Tregs with IL-6 
promotes a Th17 phenotype (27). Given that Tregs from the thymus are auto-antigen 
reactive and that a later burst of IL-6 promotes Th17 cells, this could constitute a mechanism 
for central tolerance escape. 
Studies in mouse autoimmune models have shown that knocking out Tregs favors 
autoimmunity. In T1D studies there remains disparity as to the role of Tregs in controlling 
disease. It has been reported in mouse (28) and in human (29) T1D subjects that the actual 
number and function of Tregs is normal. An interesting observation was made however that 
Tregs from pancreatic lymph nodes of T1D subjects are dysregulated in function (30), when 
compared to Tregs from peripheral blood. Another study has shown that regulatory CD8+ T 
cells that recognize the atypical HLA-E presenting the self – antigen Hsp60 are defective in 
T1D (31).  This suggests that the disparity in Treg number and function in autoimmune 
disease may relate to the location and classification of the Tregs.  
4. Th40 cells: a biomarker for pathogenic effector T cells 
In numerous studies CD40 has been identified as a biomarker for auto-aggressive T cells (19, 
28, 32-36).  A panel of highly pathogenic, auto-aggressive T cell clones, including the well 
described BDC2.5 clone express CD40 (34-36).  Although CD40 has been typically associated 
with antigen presenting cells, it was demonstrated on primary T cells in NOD mice, the type 
1 diabetes model, and in the process identified a unique effector CD4+ T cell population, 
characterized as CD4+CD40+ [Th40] (19, 28, 32-37). Importantly, Th40 cells were detected in 
both autoimmune and non-autoimmune mouse strains but occurring at a significantly 
greater percentage and cell number in autoimmunity (19, 28, 32-35). In fact, the percentage 
of Th40 cells increased proportionately with increasing insulitis leading to eventual diabetes 
in NOD mice (34). Primary Th40 cells isolated directly from the pancreata of pre-diabetic 
and diabetic NOD mice transferred progressive insulitis and diabetes to NOD.scid recipients 
(34, 36), demonstrating pathogenicity of these T cells. In other studies it was shown that 
Th40 cells are sufficient and necessary for T1D transfer (28, 36, 38, 39). CD40 depleted and 
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Treg depleted T cells are incapable of disease transfer, even when those cells are pre-
activated (28). 
 Extending these studies, Th40 cells are highly significantly expanded in human T1D, but 
not in T2D or control subjects (19). Th40 cells from T1D subjects were responsive to diabetes 
associated antigens including insulin peptides, GAD peptides and whole islets. Th40 cells 
from T1D subjects but not from controls proliferate when exposed to self-antigens and are 
induced to produce and secrete cytokines. Typically Th1 cytokines are favored (19). 
However it was further demonstrated that Th40 cells also can produce IL-17 and 
furthermore that a subset of Th40 cells produce IL-17 and IFN at the same time (40). As 
such, Th40 cells can be categorized between Th1 and Th17 phenotypes having characteristics 
of both (Fig. 1). Another interesting feature is that Th40 cells from human T1D subjects 
produce a substantially elevated level of IL-6; but unlike the other cytokines produced by 
these T cells, IL-6 production is not dependent upon antigen recognition (19). This could 
align with the notion that autoimmune diabetes favors a loss of Tregs by providing a 
mechanism to convert Tregs to Th17 cells (Fig. 1). This process may proceed through the 
Th40 subset, which as mentioned are greatly expanded in number in T1D (19, 28, 32, 35-41). 
Blocking CD40 interaction with its natural ligand CD154 provides a useful treatment 
strategy in autoimmunity and T1D in particular. CD40 – CD154 interactions have proven 
crucial in several autoimmune diseases including T1D (42-44). Blocking CD40 – CD154 
interactions at 3-weeks of age in NOD mice prevents T1D onset (44). Taken further, blocking 
CD40 – CD154 interactions in NOD prevented the expansion of auto-aggressive T cells 
while allowing expansion of innate regulatory, CD4+CD25+ T cells (34).  Thus, blocking 
CD40 – CD154 interaction restores T cell homeostasis. CD154 is temporally induced on 
activated T cells (45, 46), is found on platelets (47-49), smooth muscle, vascular endothelial 
cells and antigen presenting cells (50). CD154 is a member of the TNF super-family, 
demonstrating high protein sequence homology with TNF (51). Like TNF, CD154 occurs in a 
soluble form and may behave as a cytokine (52, 53). Interestingly, CD154 including the 
soluble form is hyper-expressed in T1D (54).  
5. T cell co-stimulation and disease 
A primary paradigm of immunology states that T cells require two signals to achieve 
effector status; an antigen specific recognition signal and a second co-stimulus (55). The 
classic T cell co-stimulus is CD28 on T cells interacting with B7 on APC. However CD28-/- 
mice that did not develop disease after initial injections, developed fulminant EAE after a 
second round of induction (56) . In that model a faster, more severe EAE occurred in the 
absence of the CD28 T cell co-stimulatory pathway. It has been repeatedly shown that TCR 
engagement alone is insufficient for effector functions. Given that T cells require a co-
stimulus for activation the above study suggests a second, perhaps more pernicious T cell 
co-stimulatory mechanism. Interestingly in that study, blocking CD40 – CD154 through 
administration of an anti-CD154 resulted in significant long-term inhibition of clinical EAE 
relapse (56). While CD40 signaling directly impacts antigen presenting cells, in contrast to 
established paradigms, CD40 has been shown to function effectively as a T cell co-stimulus 
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6. Th40 cells and TCR revision 
Another paradigm of immunology holds that TCR molecules are generated in the thymus 
without further alteration. However, it has been demonstrated that RAG1 and RAG2, the 
recombinase proteins that are responsible for TCR generation, are inducible in peripheral T 
cells (35, 60-70). Following induction of RAGs, altered expression of TCR (34, 35) and TCR 
(64, 65, 71) molecules on peripheral T cells, (TCR revision) was demonstrated. This has 
serious implications for T cell function and autoimmune potential. TCR revision could 
directly create auto-aggressive T cells that would not be negatively selected. Regardless of 
whether auto-aggressive T cells are thymic escapees or generated in the periphery, they 
accumulate under autoimmune conditions (72). Another intriguing finding is that IL-17 
producing T cells are more likely to undergo TCR revisions (60). Cumulatively, these 
findings have direct implications for T1D and other autoimmune diseases. Eventual TCR 
revision of the initial auto-aggressive T cells could promote tolerance by altering antigen 
specificity of pathogenic T cells; thus resulting in remission. Alternatively, TCR revision by 
necessity dictates that T cells with TCR that were never exposed to thymic selection 
conditions are found in the periphery and therefore may have initiated the autoimmune 
insult. 
7. Conclusions 
T cells play a critical role in diabetogenesis as do other cells. Different categories of T cells, 
Th1, Th17 and now Th40 are being identified in this disease, yet a major concern for 
understanding and ultimately treating the disease requires a global outlook. How is it that 
each of these cell types contribute to the overall disease and how do they work in concert to 
establish and maintain debilitating inflammation. Controlling the inflammatory process 
without inducing unwanted immune suppression will require surgical precision. It is likely 
that no one treatment option will prove completely successful, and focusing on any one cell 
type will diminish the ability to comprehend the overall picture of the disease process. 
Creating a comprehensive framework of study will be essential for successful treatment. 
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